SCHEMBL12438424

SCHEMBL12438424

Cc1ccccc1Nc1ncc([N+](=O)[O-])c(Nc2cc(C3CC3)n[nH]2)n1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IGF1R P08069 9/20 0.59
ALK Q9UM73 2/20 0.46
GSK3B P49841 4/20 0.45
PLK1 P53350 2/20 0.42
LRRK2 Q5S007 1/20 0.42
GSK3A P49840 3/20 0.41
PRKCQ Q04759 2/20 0.41
MAPT P10636 2/20 0.41
KMT2A Q03164 2/20 0.41
HPGD P15428 1/20 0.41
CDC7 O00311 1/20 0.40
PLK4 O00444 1/20 0.40
CHEK1 O14757 1/20 0.40
DCLK1 O15075 1/20 0.40
CHUK O15111 1/20 0.40
PDPK1 O15530 1/20 0.40
DAPK3 O43293 1/20 0.40
DYRK3 O43781 1/20 0.40
JAK2 O60674 1/20 0.40
ROCK2 O75116 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11348892 0.90 IGF1R (0.73) IGF1RGSK3BGSK3APRKCQDCLK1
SCHEMBL12439767 0.86 IGF1R (0.58) IGF1RLRRK2CDK2CDK5
SCHEMBL12437982 0.84 IGF1R (0.69) IGF1R
SCHEMBL11938857 0.84 IGF1R (0.56) IGF1RLRRK2CDK2CDK5
SCHEMBL11342483 0.83 IGF1R (0.59) IGF1RGSK3BGSK3APRKCQMAPT
SCHEMBL14161874 0.83 IGF1R (0.53) IGF1RLRRK2AURKA
SCHEMBL12438227 0.81 IGF1R (0.49) IGF1RALKLRRK2MET
SCHEMBL14050613 0.81 IGF1R (0.51) IGF1RLRRK2CDK2CDK5
SCHEMBL12439422 0.80 IGF1R (0.66) IGF1R
SCHEMBL14050422 0.79 IGF1R (0.65) IGF1RMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1841760-B1 PYRIMIDINE DERIVATIVES AS KINASE MODULATORS AND METHOD OF USE EXELIXIS INC (US) 2011-08-10 EP disclosed
WO-2008127594-A2 COMBINATION THERAPIES COMPRISING QUINOXALINE INHIBITORS OF PI3K-ALPHA FOR USE IN THE TREATMENT OF CANCER EXELIXIS, INC. (US) 2008-10-23 WO disclosed
WO-2008076415-A1 METHODS OF USING MEK INHIBITORS EXELIXIS, INC. (US) 2008-06-26 WO disclosed
WO-2008005538-A2 METHODS OF USING IGF1R AND ABL KINASE MODULATORS EXELIXIS, INC. (US) 2008-01-10 WO disclosed